Apricus Biosciences, Inc (NASDAQ:APRI)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Friday. They presently have a $4.50 price target on the stock. HC Wainwright’s target price indicates a potential upside of 186.62% from the stock’s previous close.

Separately, Zacks Investment Research downgraded Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Friday, August 4th.

Apricus Biosciences (APRI) traded down $0.12 on Friday, reaching $1.57. The company’s stock had a trading volume of 376,912 shares, compared to its average volume of 207,321. Apricus Biosciences has a one year low of $0.86 and a one year high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same period in the prior year, the firm posted ($0.19) earnings per share. equities analysts predict that Apricus Biosciences will post -0.81 earnings per share for the current fiscal year.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/04/hc-wainwright-reiterates-buy-rating-for-apricus-biosciences-inc-apri.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.